Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A
Could Have £12bn To Spend On M&A
GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.
You may also be interested in...
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
‘New GSK’ Raises Outlook After Shingrix Hits New Heights
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.